“: We are reiterating our Overweight rating and increasing our price target to $35/share from $28/share on Krystal Biotech. This morning, Krystal announced and held a conference call to discuss interim results from two patients in the ongoing Phase 1/2 study (GEM) of KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). The trial met all primary efficacy endpoints for the two patients and showed substantial improvements in time to wound closure, in our view. Importantly, KB103 was well tolerated with no serious adverse events or product- related adverse events reported. Krystal remains on track to complete the study in 1H19.”,” Cantor Fitzgerald’s analyst commented.
Other equities analysts also recently issued research reports about the stock. LADENBURG THALM/SH SH set a $38.00 price objective on shares of Krystal Biotech and gave the stock a buy rating in a report on Thursday, July 19th. HC Wainwright began coverage on shares of Krystal Biotech in a report on Monday, September 24th. They set a buy rating and a $32.00 price target for the company. ValuEngine raised shares of Krystal Biotech from a hold rating to a buy rating in a report on Friday, September 21st. Zacks Investment Research raised shares of Krystal Biotech from a hold rating to a buy rating and set a $18.00 price target for the company in a report on Saturday, August 11th. Finally, Chardan Capital reissued a buy rating and set a $35.00 price target on shares of Krystal Biotech in a report on Monday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $31.60.
Shares of KRYS traded up $1.49 during mid-day trading on Monday, reaching $22.34. 56,207 shares of the stock traded hands, compared to its average volume of 167,790. The firm has a market capitalization of $313.68 million, a P/E ratio of -15.09 and a beta of -0.81. Krystal Biotech has a 12-month low of $8.03 and a 12-month high of $24.89.
Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 5th. The company reported ($0.26) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.26). As a group, analysts forecast that Krystal Biotech will post -1 earnings per share for the current year.
In other Krystal Biotech news, insider Krish S. Krishnan purchased 25,000 shares of the company’s stock in a transaction on Thursday, October 18th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 45.80% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC increased its stake in Krystal Biotech by 552.2% in the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares in the last quarter. BlackRock Inc. increased its stake in Krystal Biotech by 75.4% in the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares in the last quarter. P.A.W. Capital Corp purchased a new position in Krystal Biotech in the 3rd quarter worth about $527,000. Finally, JPMorgan Chase & Co. increased its stake in Krystal Biotech by 69.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after purchasing an additional 14,755 shares in the last quarter. Hedge funds and other institutional investors own 22.04% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.